L‑DOPA, also called levodopa, is a naturally occurring amino acid derivative that serves as the immediate biochemical precursor of the catecholamine neurotransmitters. In mammals it is produced from the amino acid tyrosine and is converted enzymatically to dopamine. Unlike dopamine itself, L‑DOPA can cross the blood–brain barrier, which underlies both its physiological role and its medical importance.

Chemical nature and biochemical role

Chemically, L‑DOPA is the levorotatory isomer of 3,4‑dihydroxyphenylalanine and is not incorporated into proteins. In the central nervous system it is formed from tyrosine by the action of tyrosine hydroxylase. Aromatic L‑amino acid decarboxylase (also called DOPA decarboxylase) then converts L‑DOPA to dopamine. Dopamine can be further metabolized to norepinephrine and epinephrine in noradrenergic and adrenergic cells by dopamine β‑hydroxylase and phenylethanolamine N‑methyltransferase.

Medical use and pharmacology

Levodopa is the most effective symptomatic treatment for the bradykinesia, rigidity and tremor of Parkinson's disease. Because much L‑DOPA is decarboxylated to dopamine outside the brain, clinical formulations are normally combined with a peripheral decarboxylase inhibitor (for example carbidopa or benserazide) to increase central availability and reduce peripheral side effects. Over time many patients develop motor complications such as fluctuations in benefit and involuntary movements (dyskinesias).

Occurrence, supplementation and side effects

L‑DOPA occurs naturally in some plants, most famously in fava beans and certain legumes, and is available as a dietary supplement in some markets. Common adverse effects when used therapeutically include nausea, orthostatic hypotension, hallucinations and sleep disturbances; interactions with other drugs that affect monoamine metabolism are clinically important.

History and scientific significance

The realization that dopamine is a central neurotransmitter and the discovery that dopamine deficiency underlies many Parkinsonian signs were pivotal milestones in mid‑20th century neuroscience. Those insights led to trials of L‑DOPA as a replacement therapy and to the development of strategies that limit peripheral conversion and optimize central delivery.

Further reading and resources